Screenshot 2020-09-16 at 5.20.15 PM
Saturday, April 4, 2026
22.6
C
Bengaluru
Hot topics
DeepSeek – A Precursor to Patent Disruption?
The rise of open-source platforms, such as China’s DeepSeek...
Finding the middle ground for Doctor-Stakeholder Relationship
Healthcare systems around the world differ – public, private or a mix of both public and private (like in India). With all the variance in healthcare delivery models, the risks to healthcare professionals remain universal: needle injuries to litigations to episodes of threats/ violence
An Invitation from the Editor
FFE and BrandStorm 2016 Agenda inside. Articles by Raja Reddy, K. Hariram, Amit Jain, and Vivek Hattangadi.
Role of AI Across Pharma Industry
Introduction
Artificial intelligence (AI) is increasingly pivotal in driving innovation...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hot topics
Talent Management
A diverse, summer issue with articles on topics ranging from content marketing to the role of experience in a VUCA world. Also, the latest book for Medical Reps reviewed by Prof. Vivek Hattangadi
How to Influence Patients to Adopt Healthy Lifestyle or Improve Adherence?
One of the many ways of influencing patients to...
India’s Medical Devices Market: Strategic Implications and Key Investors
KKR's Investments in India's Medical Devices Market: Strategic Implications...
If Strategy is Commodity, How Can Organisations Ensure Differentiation?
Strategy and strategic planning are perhaps the most hyped-up...
An Infectious Disease Specialist Speaks to Pharma on How it Needs to Change its Approach
Key Point from the Q &A with Dr. Mandar...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare
When drones first appeared on battlefields, military establishments reacted...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India
How the 2026 U.S. tariff action on branded drugs...
Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?
The "aspirinization" of obesity—moving from a niche, high-cost injectable...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
Newsletter
Get important news delivered directly to your inbox and stay connected!